Telix Pharmaceuticals (TLX) Total Debt (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Total Debt data on file, last reported at $405.0 million in Q4 2025.

• Total Debt for Q4 2025 came in at $405.0 million, up 8.5% year-over-year; the trailing twelve-month figure through Dec 2025 was $405.0 million (up 8.5% YoY), and the FY2025 annual result was $405.0 million, up 8.5% from the prior year.
• Total Debt rose to $405.0 million in Q4 2025 per TLX's latest filing, from $373.3 million in the prior quarter.
• Over five years, Total Debt peaked at $405.0 million in Q4 2025 and troughed at $6.0 million in Q4 2023.
• A 3-year average of $261.4 million and a median of $373.3 million in 2024 frame the typical range for Total Debt.
• The sharpest annual moves came in 2024 and 2025: Total Debt soared 6151.08% in 2024, then rose 8.5% in 2025.
• A 3-year view of Total Debt shows it stood at $6.0 million in 2023, then soared by 6151.08% to $373.3 million in 2024, then grew by 8.5% to $405.0 million in 2025.
• Business Quant data shows TLX's Total Debt at $405.0 million in Q4 2025, $373.3 million in Q4 2024, and $6.0 million in Q4 2023.